Please assess the completion status of the following clinical trial:

Trial Title: WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75 years, inclusive~* Diagnosed with type 2 diabetes~* Stable dose of sulfonylurea alone or in combination with other anti-diabetic medications for 90 days~* Hemoglobin A1c value 7.5% to 9.5%, inclusive~* C peptide \> 0.5 ng/mL~* Prescribed ADA diet~Exclusion Criteria:~* History of type 1 diabetes or ketoacidosis~* History of pancreatitis~* Uncontrolled hypertension~* Allergy or toxic response to colesevelam or any of its components~* Serum LDL-C \< 60 mg/dL~* Serum TG \> 500 mg/dL~* Body mass index (BMI) \> 45 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).